These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37977714)

  • 1. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
    Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
    Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study.
    Wan G; Chen W; Khattab S; Roster K; Nguyen N; Yan B; Rajeh A; Seo J; Rashdan H; Zubiri L; Hadfield MJ; Demehri S; Yu KH; Lotter W; Gusev A; LeBoeuf NR; Reynolds KL; Kwatra SG; Semenov YR
    Lancet Oncol; 2024 Aug; 25(8):1053-1069. PubMed ID: 39025103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
    Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study.
    Farina A; Villagrán-García M; Fourier A; Pinto AL; Chorfa F; Timestit N; Alberto T; Aupy J; Benaiteau M; Birzu C; Campetella L; Cotton F; Dalle S; Delaruelle CF; Dumez P; Germi R; Le Maréchal M; Maillet D; Marignier R; Pegat A; Psimaras D; Rafiq M; Picard G; Desestret V; Quadrio I; Honnorat J; Joubert B
    Lancet Reg Health Eur; 2024 Sep; 44():101011. PubMed ID: 39170102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.
    Diamanti L; Picca A; Bini P; Gastaldi M; Alfonsi E; Pichiecchio A; Rota E; Rudà R; Bruno F; Villani V; Galiè E; Vogrig A; Valente M; Zoccarato M; Poretto V; Giometto B; Cimminiello C; Del Vecchio M; Marchioni E
    Neurol Sci; 2022 Mar; 43(3):2031-2041. PubMed ID: 34424427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity.
    Farina A; Birzu C; Elsensohn MH; Picca A; Muñiz-Castrillo S; Vogrig A; Villagrán-García M; Ciano-Petersen NL; Massacesi L; Hervier B; Guégan S; Kramkimel N; Vano Y; Salem JE; Allenbach Y; Maisonobe T; Assaad S; Maureille A; Devic P; Weiss N; Pegat A; Maucort-Boulch D; Ricard D; Honnorat J; Psimaras D; Joubert B
    Brain Commun; 2023; 5(3):fcad169. PubMed ID: 37389303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
    Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
    Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study.
    Armangue T; Olivé-Cirera G; Martínez-Hernandez E; Sepulveda M; Ruiz-Garcia R; Muñoz-Batista M; Ariño H; González-Álvarez V; Felipe-Rucián A; Jesús Martínez-González M; Cantarín-Extremera V; Concepción Miranda-Herrero M; Monge-Galindo L; Tomás-Vila M; Miravet E; Málaga I; Arrambide G; Auger C; Tintoré M; Montalban X; Vanderver A; Graus F; Saiz A; Dalmau J;
    Lancet Neurol; 2020 Mar; 19(3):234-246. PubMed ID: 32057303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis.
    Armangue T; Spatola M; Vlagea A; Mattozzi S; Cárceles-Cordon M; Martinez-Heras E; Llufriu S; Muchart J; Erro ME; Abraira L; Moris G; Monros-Giménez L; Corral-Corral Í; Montejo C; Toledo M; Bataller L; Secondi G; Ariño H; Martínez-Hernández E; Juan M; Marcos MA; Alsina L; Saiz A; Rosenfeld MR; Graus F; Dalmau J;
    Lancet Neurol; 2018 Sep; 17(9):760-772. PubMed ID: 30049614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
    Vilaseca A; Farina A; Villagrán-García M; Pegat A; Benaiteau M; Ciano-Petersen NL; Do LD; Rogemond V; Gonçalves D; Psimaras D; Birzu C; Honnorat J; Joubert B
    J Neurol; 2024 Jun; 271(6):3279-3290. PubMed ID: 38467790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
    Vicino A; Hottinger AF; Latifyan S; Boughdad S; Becce F; Prior JO; Kuntzer T; Brouland JP; Dunet V; Obeid M; Théaudin M
    J Neurol; 2024 Apr; 271(4):1947-1958. PubMed ID: 38141128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
    Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
    Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
    Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
    Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study.
    Muñoz-Lopetegi A; Guasp M; Prades L; Martínez-Hernández E; Rosa-Justícia M; Patricio V; Armangué T; Rami L; Borràs R; Castro-Fornieles J; Compte A; Gaig C; Santamaria J; Dalmau J;
    Lancet Neurol; 2024 Mar; 23(3):256-266. PubMed ID: 38365378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
    Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R
    Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review.
    Chen Y; Jia Y; Liu Q; Shen Y; Zhu H; Dong X; Huang J; Lu J; Yin Q
    Ann Palliat Med; 2021 Jul; 10(7):8512-8517. PubMed ID: 34263614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
    Farina A; Villagrán-García M; Honnorat J
    Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
    Möhn N; Sühs KW; Gingele S; Angela Y; Stangel M; Gutzmer R; Satzger I; Skripuletz T
    Melanoma Res; 2019 Aug; 29(4):435-440. PubMed ID: 30855529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
    Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.